Literature DB >> 14666638

Tumor markers as prognostic factors in treated non-small cell lung cancer.

Jaume Trapé1, Josep Buxo, Joaquim Pérez de Olaguer, Carmen Vidal.   

Abstract

The usefulness of tumor markers in non-small cell lung carcinoma (NSCLC) is not well defined. The aim of this study was to determine the predictive value for response to treatment and prognosis of pretreatment concentrations of tumor markers. The pretreatment levels of CEA, CA125 and CYFRA21-1 were determined by electrochemoluminiscence in 48 patients with advanced stage (IIIA-IV) NSCLC treated with platin-based chemotherapy. The sensitivity for CYFRA21-1, CA125 and CEA was 66.7%, 45.8% and 47.3%, respectively. The predictive factors for non-response to treatment were CA125 > 35 KU/L (OR = 5.36; p = 0.017) and presence of metastasis (OR = 6.92; p = 0.007). The prognostic factors for survival were Performance Status > 1 (HR = 4.22; p = 0.0002), presence of metastasis (HR = 3.1; p = 0.0028) and CA125 > 35 KU/L (HR = 2.33; p = 0.02). In conclusion, CA125 is a predictive factor for response to treatment and a prognostic factor for survival in patients with NSCLC treated with chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14666638

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Correlation between serum CEA levels and EGFR mutations in Chinese nonsmokers with lung adenocarcinoma.

Authors:  Bo Jin; Yu Dong; Hui-min Wang; Jin-su Huang; Bao-hui Han
Journal:  Acta Pharmacol Sin       Date:  2014-02-03       Impact factor: 6.150

Review 2.  History, molecular features, and clinical importance of conventional serum biomarkers in lung cancer.

Authors:  Haruhiko Nakamura; Toshihide Nishimura
Journal:  Surg Today       Date:  2017-02-22       Impact factor: 2.549

Review 3.  Carcinoembryonic antigen and cytokeratin-19 fragments for assessment of therapy response in non-small cell lung cancer: a systematic review and meta-analysis.

Authors:  Stefan Holdenrieder; Birgit Wehnl; Karina Hettwer; Kirsten Simon; Steffen Uhlig; Farshid Dayyani
Journal:  Br J Cancer       Date:  2017-03-09       Impact factor: 7.640

4.  Prognostic value of serum cytokeratin 19 fragments (Cyfra 21-1) in patients with non-small cell lung cancer.

Authors:  Youtao Xu; Lei Xu; Mantang Qiu; Jie Wang; Qing Zhou; Lin Xu; Jian Wang; Rong Yin
Journal:  Sci Rep       Date:  2015-04-22       Impact factor: 4.379

5.  SUVmax Predicts Disease Progression after Stereotactic Ablative Radiotherapy in Stage I Non-small Cell Lung Cancer.

Authors:  Yoo-Kang Kwak; Hee Hyun Park; Kyu Hye Choi; Eun Young Park; Soo Yoon Sung; Sea-Won Lee; Ji Hyun Hong; Hyo Chun Lee; Ie Ryung Yoo; Yeon Sil Kim
Journal:  Cancer Res Treat       Date:  2019-05-17       Impact factor: 4.679

6.  Tumor response and survival in patients with advanced non-small-cell lung cancer: the predictive value of chemotherapy-induced changes in fibrinogen.

Authors:  Jun Zhao; Mingfang Zhao; Bo Jin; Ping Yu; Xuejun Hu; Yuee Teng; Jingdong Zhang; Ying Luo; Lingyun Zhang; Shuang Zheng; Qiyin Zhou; Heming Li; Yunpeng Liu; Xiujuan Qu
Journal:  BMC Cancer       Date:  2012-08-01       Impact factor: 4.430

7.  The relationship between Glasgow Prognostic Score and serum tumor markers in patients with advanced non-small cell lung cancer.

Authors:  Ai-Gui Jiang; Hong-Lin Chen; Hui-Yu Lu
Journal:  BMC Cancer       Date:  2015-05-10       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.